{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:44:47Z","timestamp":1790106287707,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s12325-022-02221-2","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T14:04:51Z","timestamp":1656684291000},"page":"4061-4075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Adherence to Adjuvant Therapy in Patients with Resected Melanoma: An Application of the Theory of Planned Behavior"],"prefix":"10.1007","volume":"39","author":[{"given":"Cassie","family":"Beisel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayla","family":"Poretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa B.","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Hurtado-de Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Sipsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanore","family":"Fuqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Stwalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"2221_CR1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Mathers C, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941\u201353.","journal-title":"Int J Cancer"},{"key":"2221_CR2","unstructured":"American Cancer Society. Cancer facts & figures 2021. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2021\/cancer-facts-and-figures-2021.pdf. Accessed 09 February 2021."},{"key":"2221_CR3","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/JCO.2009.26.2063","volume":"28","author":"E Romano","year":"2010","unstructured":"Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage\u00a0III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28:3042\u20137.","journal-title":"J Clin Oncol"},{"key":"2221_CR4","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AMM Eggermont","year":"2015","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage\u00a0III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522\u201330.","journal-title":"Lancet Oncol"},{"key":"2221_CR5","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage\u00a0III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845\u201355.","journal-title":"N Engl J Med"},{"key":"2221_CR6","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","volume":"21","author":"GT Gibney","year":"2015","unstructured":"Gibney GT, Kudchadkar RR, DeConti RC, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21:712\u201320.","journal-title":"Clin Cancer Res"},{"key":"2221_CR7","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Melanoma: Cutaneous V.3.2022. \u00a9 National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed 25 April 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"2221_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","volume":"134","author":"CC Murphy","year":"2012","unstructured":"Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134:459\u201378.","journal-title":"Breast Cancer Res Treat"},{"key":"2221_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2147\/PPA.S126651","volume":"11","author":"Z Moon","year":"2017","unstructured":"Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD. Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Pref Adherence. 2017;11:305\u201322.","journal-title":"Patient Pref Adherence"},{"issue":"4 suppl","key":"2221_CR10","first-page":"87","volume":"21","author":"LA Kottschade","year":"2017","unstructured":"Kottschade LA, Lehner RM. Promoting oral therapy adherence: consensus statements from the faculty of the melanoma nursing initiative on oral melanoma therapies. Clin J Oncol Nurs. 2017;21(4 suppl):87\u201396.","journal-title":"Clin J Oncol Nurs"},{"key":"2221_CR11","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2147\/PPA.S106629","volume":"10","author":"D Eek","year":"2016","unstructured":"Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Pref Adherence. 2016;10:1609\u201321.","journal-title":"Patient Pref Adherence"},{"key":"2221_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0749-5978(91)90020-T","volume":"50","author":"I Ajzen","year":"1991","unstructured":"Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Processes. 1991;50:179\u2013211.","journal-title":"Organ Behav Hum Decis Processes"},{"key":"2221_CR13","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/08870446.2010.542815","volume":"26","author":"M Manning","year":"2011","unstructured":"Manning M, Bettencourt BA. Depression and medication adherence among breast cancer survivors: bridging the gap with the theory of planned behaviour. Psychol Health. 2011;26:1173\u201387.","journal-title":"Psychol Health"},{"key":"2221_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.yebeh.2016.05.030","volume":"61","author":"C-Y Lin","year":"2016","unstructured":"Lin C-Y, Updegraff JA, Pakpour AH. The relationship between the theory of planned behavior and medication adherence in patients with epilepsy. Epilepsy Behav. 2016;61:231\u20136.","journal-title":"Epilepsy Behav"},{"key":"2221_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/pon.4931","volume":"28","author":"A Hurtado-de-Mendoza","year":"2019","unstructured":"Hurtado-de-Mendoza A, Carrera P, Parrott WG, G\u00f3mez-Trillos S, Perera RA, Sheppard VB. Applying the theory of planned behavior to examine adjuvant endocrine therapy adherence intentions. Psychooncology. 2019;28:187\u201394.","journal-title":"Psychooncology"},{"key":"2221_CR16","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/bjhp.12274","volume":"22","author":"Z Moon","year":"2017","unstructured":"Moon Z, Moss-Morris R, Hunter MS, Hughes LD. More than just side-effects: the role of clinical and psychosocial factors in non-adherence to tamoxifen. Br J Health Psychol. 2017;22:998\u20131018.","journal-title":"Br J Health Psychol"},{"key":"2221_CR17","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s11606-021-06648-1","volume":"36","author":"KQE Peh","year":"2021","unstructured":"Peh KQE, Kwan YH, Goh H, et al. An adaptable framework for factors contributing to medication adherence: results from a systematic review of 102 conceptual frameworks. J Gen Intern Med. 2021;36:2784\u201395.","journal-title":"J Gen Intern Med"},{"key":"2221_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10865-015-9644-3","volume":"38","author":"A Rich","year":"2015","unstructured":"Rich A, Brandes K, Mullan B, Hagger MS. Theory of planned behavior and adherence in chronic illness: a meta-analysis. J Behav Med. 2015;38:673\u201388.","journal-title":"J Behav Med"},{"key":"2221_CR19","first-page":"227","volume":"22","author":"BS Seal","year":"2016","unstructured":"Seal BS, Anderson S, Shermock KM. Factors associated with adherence rates for oral and intravenous anticancer therapy in commercially insured patients with metastatic colon cancer. J Manag Care Spec Pharm. 2016;22:227\u201335.","journal-title":"J Manag Care Spec Pharm"},{"key":"2221_CR20","first-page":"163","volume":"5","author":"SM Schneider","year":"2014","unstructured":"Schneider SM, Adams DB, Gosselin T. A tailored nurse coaching intervention for oral chemotherapy adherence. J Adv Pract Oncol. 2014;5:163\u201372.","journal-title":"J Adv Pract Oncol"},{"key":"2221_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12885-020-07538-1","volume":"21","author":"K Toor","year":"2021","unstructured":"Toor K, Middleton MR, Chan K, Amadi A, Moshyk A, Kotapati S. Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis. BMC Cancer. 2021;21:3.","journal-title":"BMC Cancer"},{"key":"2221_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/21556660.2019.1649266","volume":"8","author":"M Lorenzi","year":"2019","unstructured":"Lorenzi M, Arndorfer S, Aguiar-Iba\u00f1ez R, Scherrer E, Liu FX, Krepler C. An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage\u00a0III melanoma. J Drug Assess. 2019;8:135\u201345.","journal-title":"J Drug Assess"},{"key":"2221_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12885-017-3110-2","volume":"17","author":"L Timmers","year":"2017","unstructured":"Timmers L, Boons CCLM, Verbrugghe M, van den Bemt BJF, Van Hecke A, Hugtenburg JG. Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists. BMC Cancer. 2017;17:122.","journal-title":"BMC Cancer"},{"key":"2221_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.clbc.2014.04.005","volume":"14","author":"H Wouters","year":"2014","unstructured":"Wouters H, Stiggelbout AM, Bouvy ML, et al. Endocrine therapy for breast cancer: assessing an array of women\u2019s treatment experiences and perceptions, their perceived self-efficacy and nonadherence. Clin Breast Cancer. 2014;14:460-467.e2.","journal-title":"Clin Breast Cancer"},{"key":"2221_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12905-019-0772-8","volume":"19","author":"AL DeMaria","year":"2019","unstructured":"DeMaria AL, Sundstrom B, Faria AA, Moxley Saxon G, Ramos-Ortiz J. Using the theory of planned behavior and self-identity to explore women\u2019s decision-making and intention to switch from combined oral contraceptive pill (COC) to long-acting reversible contraceptive (LARC). BMC Womens Health. 2019;19:82.","journal-title":"BMC Womens Health"},{"key":"2221_CR26","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage\u00a0III or IV melanoma. N Engl J Med. 2017;377:1824\u201335.","journal-title":"N Engl J Med"},{"key":"2221_CR27","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2340\/00015555-2944","volume":"98","author":"S Ribero","year":"2018","unstructured":"Ribero S, Stucci LS, Marra E, et al. Effect of age on melanoma risk, prognosis and treatment response. Acta Derm Venereol. 2018;98:624\u20139.","journal-title":"Acta Derm Venereol"},{"key":"2221_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/12034754211052866","volume":"26","author":"M Lam","year":"2022","unstructured":"Lam M, Zhu JW, Hu A, Beecker J. Racial differences in the prognosis and survival of cutaneous melanoma from 1990 to 2020 in North America: a systematic review and meta-analysis. J Cutan Med Surg. 2022;26:181\u20138.","journal-title":"J Cutan Med Surg"},{"key":"2221_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/09546634.2019.1657223","volume":"31","author":"O Abdel-Rahman","year":"2020","unstructured":"Abdel-Rahman O. Prognostic impact of socioeconomic status among patients with malignant melanoma of the skin: a population-based study. J Dermatolog Treat. 2020;31:571\u20135.","journal-title":"J Dermatolog Treat"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02221-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02221-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02221-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T09:53:22Z","timestamp":1661334802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02221-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2221"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02221-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"assertion":[{"value":"8 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}